Endo International PLC (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX) Critical Review
Endo International PLC (NASDAQ: ENDP) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.
Insider and Institutional Ownership
90.5% of Endo International PLC shares are owned by institutional investors. Comparatively, 0.1% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. 0.5% of Endo International PLC shares are owned by company insiders. Comparatively, 12.1% of RegeneRx Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Endo International PLC and RegeneRx Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Endo International PLC||$4.01 billion||0.42||-$3.35 billion||($22.45)||-0.34|
RegeneRx Biopharmaceuticals has higher revenue, but lower earnings than Endo International PLC. Endo International PLC is trading at a lower price-to-earnings ratio than RegeneRx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for Endo International PLC and RegeneRx Biopharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Endo International PLC||1||15||4||0||2.15|
Endo International PLC presently has a consensus target price of $11.81, suggesting a potential upside of 56.66%. RegeneRx Biopharmaceuticals has a consensus target price of $1.50, suggesting a potential upside of 435.71%. Given RegeneRx Biopharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe RegeneRx Biopharmaceuticals is more favorable than Endo International PLC.
This table compares Endo International PLC and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Endo International PLC||-126.97%||66.98%||8.38%|
Risk & Volatility
Endo International PLC has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of -2.7, suggesting that its stock price is 370% less volatile than the S&P 500.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.